What developments or innovations are you expecting in the coming year that could make an impact on the overall practice of dermatology?
Robert Brodell, MD: New biologic drugs on the horizon will continue to improve our ability to take care of patients with the “heartbreak of psoriasis.” Using Big Data to understand outcomes over a huge population base and being able to benchmark our practices against this data offers an important, reletively inexpenisve method of improving patient care.
Seemal Desai, MD: Continued improvement in psoriasis and melanoma therapy, including the availability of new biologic type drugs for each of those respective disease states. Looking forward to afalomelanotide being approved for vitiligo treatment.
Joseph Jorizzo, MD: Over the next five years, most dermatologists will work for a network either through venture capital sale or direct recruitment. Drug choices will be limited by network choices, and there will be less research due to less NIH and Pharma funding.
Peter Lio, MD: I'm very excited about the development of a new topical and new systemic agent for atopic dermatitis. This troubling disease seems to be causing more trouble than ever before, and I now have a group of patients who has failed all of the old standards: topical steroids and TCIs, wet wraps, phototherapy, cyclosporine, mycophenolate, and azathioprine. We are truly ready for new ideas and new therapies in treating atopic dermatitis!
Mark Bechtel, MD: The continued development of newer biologic agents for the management of psoriasis will narrow the immunologic targets, while improving efficacy and potentially decreasing side-effects.
Gary Goldenberg, MD: More targeted therapy will allow us to take better care of our patients with fewer side effects of medication.
What is on your wish list for 2015, either in terms of your own professional/practice goals or in terms of the growth and advancement of the specialty?
Dr. Jorizzo: More dermatology hospitalists and more residency graduates choosing academics, medical, and pediatric dermatology.
Dr. Goldenberg: To continue to improve patient satisfaction is important. The current healthcare environment, with huge healthcare systems, can leave patients feel as if their care is impersonal. For me it's important to give each patient personal attention and care.
Dr. Desai: Personally, I am hopeful for continued success of my first office, and the growth and success of my newly opened second location.
Professionally, I am committed to continuing my involvement in national dermatology and organized medical associations and growing my leadership particularly within the AAD.
Dr. Lio: I am starting a new practice in Chicago with the idea that we are going to focus on “old fashioned” medicine. That is to say, we are striving to be a “craft beer” in a world of big business. I truly believe that patients do better with a personal touch, and providing the personal touch is our primary goal.
Sandra Marchese Johnson, MD: If I am wishing, I would love to stretch our current building without having to do construction, add more dermatologists and more services. I would also add a few more hours to my day. Lastly, I would wish for world peace and happiness for all.
Dr. Brodell: I enjoy, teaching, learning, and taking care of dermatology patients. Being from the State of Mississippi, that has caused me to see the importance of our work in an underserved community. Recruiting dermatologists to join me in this mission will be a big part of my work in the next year.